Changes in Myocardial Iron After Iron Administration

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

July 30, 2018

Study Completion Date

July 30, 2018

Conditions
Heart FailureIron-deficiency
Interventions
DRUG

Ferric carboymaltose

Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]

DRUG

Placebo (Normal saline)

Normal saline (0.9% weight/volume (w/v) NaCl)

DIAGNOSTIC_TEST

Cardiac magnetic resonance

Cardiac magnetic resonance including T2\* and T1-mapping sequences

Trial Locations (6)

46010

ERESA, Valencia

Fundación Investigación Hospital Clínico Universitario de Valencia. Instituto de Investigación Sanitaria INCLIVA., Valencia

Unknown

Hospital General de Castellón, Castellon

Hospital de Manises, Manises

Hospital General de Valencia, Valencia

Hospital la Fe, Valencia

All Listed Sponsors
lead

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

NCT03398681 - Changes in Myocardial Iron After Iron Administration | Biotech Hunter | Biotech Hunter